Thyroid cancer and radioactive iodine treatment: Learn to assign risk stratification, RAI therapy optimization and radiation risk reduction
After this lecture, attendees will be able to discuss the
1) Practice of RAI therapy has changed over the last 3 decades with a more judicious and limited use of RAI
2) The use of radioactive iodine is decreasing because of it does not improve the risk of recurrence and death in LOW RISK patients
3) Methods of optimization of RAI treatment using A) AJCC staging for risk of death, B)ATA risk assessment for risk of recurrence and C)post operative thyroglobulin and thyroglobulin antibody
